Assertio Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $9,933 | $13,542 | $49,459 | $29,222 |
Gross Profit | 1,382 | 4,437 | 30,175 | 9,277 |
EBITDA | -12,630 | -3,310 | 18,532 | 1,233 |
EBIT | -18,470 | -9,149 | 12,902 | -8,035 |
Net Income | -18,856 | -11,928 | 11,445 | -16,352 |
Net Change In Cash | 9,933 | 13,542 | 49,459 | 29,222 |
Free Cash Flow | 8,563 | -29,968 | -4,767 | 19,091 |
Cash | 33,713 | 10,229 | 38,500 | 47,086 |
Basic Shares | 6,434 | 6,420 | 7,100 | 6,398 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $118,713 | $124,961 | $152,069 | $156,234 |
Gross Profit | 53,325 | 85,734 | 125,049 | 137,486 |
EBITDA | 12,782 | 5,146 | 53,170 | 90,170 |
EBIT | -17,223 | -20,683 | 24,941 | 56,774 |
Net Income | -30,375 | -21,581 | -331,942 | 109,625 |
Net Change In Cash | 118,713 | 124,961 | 152,069 | 156,234 |
Free Cash Flow | -28,182 | 26,408 | 48,976 | 78,324 |
Cash | 10,229 | 50,588 | 73,441 | 64,941 |
Basic Shares | 6,403 | 6,351 | 4,735 | 3,644 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$2.93 |
2025-12-31 | -$1.06 |
2025-09-30 | $0.18 |
2025-06-30 | -$0.17 |